# aTyr Pharma Publishes Preclinical ATYR0101 Anti-Fibrosis Data Ahead of Planned 2027 Clinical Entry

- URL: https://stocks.freetheai.org/news/atyr-pharma-publishes-preclinical-atyr0101-anti-fibrosis-data-ahead-of-planned-94815f
- Published: 2026-10-13T12:00:00Z
- Category: company_news; sentiment: mixed; impact: low
- Symbols: [NASDAQ:ATYR](https://stocks.freetheai.org/symbols/NASDAQ-ATYR)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

aTyr Pharma, Inc. (ATYR) has published preclinical study results in the Journal of Biological Chemistry evaluating its proprietary drug candidate ATYR0101. In vivo testing demonstrated anti-fibrotic effects, benchmarking the therapeutic candidate against a nintedanib control.

The peer-reviewed research offers scientific validation for ATYR0101 as a potential treatment for fibrotic diseases. Despite the positive preclinical findings, shares of aTyr Pharma fell 12.75% to $0.2148 in recent market action.

The program is currently undergoing investigational new drug enabling studies. Future milestones for the candidate include filing an IND and initiating Phase 1 human trials, which the company expects to begin in 2027.

## Key points

- aTyr Pharma published preclinical data on ATYR0101 in the Journal of Biological Chemistry.
- In vivo testing showed anti-fibrotic effects when compared to a nintedanib control.
- ATYR0101 is in IND-enabling studies with entry into human clinical trials anticipated in 2027.
- Shares of aTyr Pharma (ATYR) fell 12.75% to $0.2148 following the announcement.

## Questions and answers

### What preclinical data did aTyr Pharma publish for ATYR0101?

aTyr Pharma published peer-reviewed data in the Journal of Biological Chemistry showing that ATYR0101 demonstrated anti-fibrotic effects in vivo compared to a nintedanib control.

### When is ATYR0101 expected to enter clinical trials?

The program is currently undergoing IND-enabling studies, with entry into human clinical trials targeted for 2027.

### How did aTyr Pharma stock perform following the news?

Shares of aTyr Pharma, Inc. (ATYR) dropped 12.75% to $0.2148 following the update.